New Antibiotic Zoliflodacin Shows Promise Against Drug-Resistant Gonorrhea

Reference TimelineLast updated
SUMMARY

Thailand approved zoliflodacin (Nuzolvence) on July 27, 2026, for the treatment of uncomplicated urogenital gonorrhea, making it the second country to do so after the U.S. FDA's approval on December 12, 2025. As of July 27, 2026: Zoliflodacin and gepotidacin (Bluejepa), approved by the U.S. FDA on December 11 and 12, 2025, respectively, are the first new treatments for gonorrhea in two decades, offering options against drug-resistant strains. Innoviva Specialty Therapeutics anticipates the launch of NUZOLVENCE® in the US market in early 2026, with a submission for approval in South Africa also planned for early 2026. The World Health Organization is developing recommendations for the use of these new oral antibiotics.

Timeline

Want updates on this thread?

Track this story

July 2026 — 2 developments

  1. Thailand Approves Zoliflodacin for Gonorrhea Treatment; WHO Developing Recommendations

    Thailand has approved zoliflodacin (Nuzolvence) on July 27, 2026, for the treatment of uncomplicated urogenital gonorrhea, making it the second country to do so after the U.S. FDA's approval. The World Health Organization (WHO) is also developing recommendations for the use of new oral antibiotics like zoliflodacin.

  2. FDA Approves Zoliflodacin and Gepotidacin for Gonorrhea Treatment

    The U.S. FDA approved two new antibiotics, zoliflodacin (Nuzolvence) and gepotidacin (Bluejepa), for the treatment of gonorrhea. These approvals, occurring on December 11 and 12, 2025, mark the first new treatments for the infection in two decades and offer options against drug-resistant strains. The World Health Organization is developing recommendations for these new oral antibiotics.

January 2026 — 2 developments

  2. Innoviva Specialty Therapeutics anticipates NUZOLVENCE® launch in US market

    Innoviva Specialty Therapeutics anticipates the launch of NUZOLVENCE® in the US market, making it available to patients.

December 2025 — 4 developments

  2. U.S. FDA approves Blujepa (gepotidacin) for uncomplicated urogenital gonorrhea

    The U.S. FDA approved a second new oral medicine, Blujepa (gepotidacin), to treat uncomplicated urogenital gonorrhea, alongside Nuzolvence (zoliflodacin). Blujepa is approved for patients 12 years and older.

  3. U.S. FDA approves NUZOLVENCE® for uncomplicated urogenital gonorrhea treatment

    The U.S. FDA approved NUZOLVENCE® (zoliflodacin) for oral suspension as a first-in-class, single-dose oral antibiotic for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents.

  4. Zoliflodacin confirmed non-inferior to standard gonorrhea therapy in Phase 3 trial

    Results from the multi-country Phase 3 clinical trial were published in The Lancet, confirming zoliflodacin's non-inferiority to the current standard combination therapy for uncomplicated urogenital gonorrhea.

November 2025 — 1 developments

  1. GARDP submits Zoliflodacin for priority review in Thailand, plans Managed Access Program

    Zoliflodacin was submitted for priority review in Thailand, with GARDP planning a Managed Access Program (MAP) to facilitate access prior to full approval.

June 2025 — 2 developments

  1. FDA Grants Zoliflodacin QIDP Status, Sets December 15, 2025 PDUFA Target Date

    The FDA granted zoliflodacin Qualified Infectious Disease Product (QIDP) status, which includes Priority Review, and set a Prescription Drug User Fee Act (PDUFA) target action date of December 15, 2025.

  2. FDA accepts New Drug Application for zoliflodacin for uncomplicated gonorrhea treatment

    The U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for zoliflodacin for the treatment of uncomplicated gonorrhea.

April 2024 — 1 developments

  1. ESCMID Global Congress Presents Positive Phase 3 Trial Data

    Further positive data from the Phase 3 trial, including details on safety and additional microbiological findings, were presented at the ESCMID Global Congress.

November 2023 — 1 developments

  1. Innoviva and GARDP announce zoliflodacin Phase 3 trial met primary endpoint

    Innoviva Specialty Therapeutics and the Global Antibiotic Research & Development Partnership (GARDP) announced that the global Phase 3 clinical trial for zoliflodacin met its primary endpoint, demonstrating non-inferiority to standard treatment.

November 2018 — 1 developments

  1. Zoliflodacin Cures 96% of Urogenital Gonorrhea Cases in Phase 2 Trial

    Results from the Phase 2 trial were published in The New England Journal of Medicine, indicating that zoliflodacin cured 96% of urogenital gonorrhea cases and was well-tolerated.

November 2014 — 1 developments

  1. Enrollment Begins for Phase 2 Zoliflodacin Clinical Trial for Gonorrhea

    Enrollment began for the Phase 2 clinical trial of zoliflodacin, an investigational oral antibiotic, for the treatment of uncomplicated gonorrhea.